Chronic oral anticoagulation (OAC) is an important decision related with stroke
thromboprophylaxis in non-valvular atrial fibrillation (NVAF). Almost a decade after the …

Abstract Background Direct oral anticoagulants (DOACs) are known to prevent thrombosis
but there is limited information about their activity on the clot formation and lysis cascade …

Non-vitamin K antagonist oral anticoagulants (NOACs) reduce the risk of thromboembolism
in patients with atrial fibrillation (AF). There has been no head-to-head comparison of the …

Objective: Oral anticoagulation (OAC) prescribed to AF patients for the prevention of
cardioembolic complications likely has the added benefit of preventing venous …

Patients with atrial fibrillation (AF) present hyperactivation of both platelets and coagulation
leading to a hypercoagulable state which contributes to an increased risk of …

Aims Approximately 20% of ischaemic stroke patients exhibit spontaneous arterial
recanalization, attributable to endogenous fibrinolysis, which strongly relates to improved …

Atrial fibrillation (AF) is the most common cardiac arrhythmia in the general population and
in patients with a history of cardiovascular disease. AF is becoming an outbreak particularly …

Atrial fibrillation (AF) as an age-related disease represents an increasing challenge to
Western societies due to its increasing prevalence, and the associated burden of stroke and …

Introduction Oral anticoagulation (OAC) significantly mitigates thromboembolism risks in
atrial fibrillation (AF) and venous thromboembolism (VTE) patients yet concern about major …

Plasma proteins mediate thrombogenesis, inflammation, endocardial injury and structural
remodelling in atrial fibrillation (AF). We hypothesised that anti-coagulation with rivaroxaban …